The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK515.00.

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

PURCHASE, NY. — Rachel Ferdinando has been promoted from president of PepsiCo Foods Canada to chief executive officer of ...